Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10510831 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10508099 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL570203 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10506976 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10735194 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL570204 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10508209 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL3060848 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10508715 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10506819 | 0.94 | TSHR (0.42) | TSHRTDP1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552176-B2 | Glycosylated chlorambucil analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-10-08 | — | — | US | claimed |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | claimed |
| US-20100267655-A1 | Glycosylated Warfarin Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | claimed |
| WO-2010014814-A2 | GLYCOSYLATED WARFARIN ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | WO | claimed |
| US-8552176-B2 | Glycosylated chlorambucil analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8278436-B2 | Glycosylated warfarin analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20100267655-A1 | Glycosylated Warfarin Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010014814-A2 | GLYCOSYLATED WARFARIN ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-0173462-B1 | ELLIPTICINE DERIVATIVE AND PRODUCTION PROCESS THEREOF | SUNTORY LIMITED (JP) | 1989-10-25 | — | — | EP | disclosed |
| US-4698423-A | ANTITUMOR AGENTS | SUNTORY LIMITED (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0173462-A2 | Ellipticine derivative and production process thereof | SUNTORY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267655-A1 | Glycosylated Warfarin Analogs and Uses Thereof | GPI, UGGT1, GALE | TSHR 2519/4885TDP1 3781/4885CHRM2 3924/4885 |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | CD22, UGGT1, UGCG | TSHR 1266/4885TDP1 3929/4885CHRM2 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.